IBTS

Infant Bacterial Therapeutics (IBT) is a clinical-stage pharmaceutical company based in Stockholm, Sweden, dedicated to developing therapies that influence the infant microbiome to treat rare and life-threatening diseases in premature babies. The company's lead drug candidate, IBP-9414, is a live biotherapeutic product containing the bacterial strain Lactobacillus reuteri, which is naturally found in human breast milk. IBP-9414 is currently in Phase 3 clinical development (The Connection Study) for the prevention of necrotizing enterocolitis (NEC) and the improvement of sustained feeding tolerance in very low birth weight infants. Beyond its lead program, IBT is advancing a pipeline that includes treatments for gastroschisis, retinopathy of prematurity, and antibiotic-resistant hospital infections. Listed on Nasdaq Stockholm, the company leverages its specialized expertise in live bacterial therapeutics to address significant unmet medical needs in neonatal care.